Camber launches mycophenolate mofetil capsules
Mycophenolate mofetil capsules are indicated for the prophylaxis of organ rejection in certain transplant patients.
Camber is releasing mycophenolate mofetil capsules.
The medication is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
[Read more: Camber debuts generic Tarceva]
Mycophenolate mofetil capsules, 250 mg are available from Camber in 100 and 500-count bottles.